康希诺生物股份公司董事会 康希诺生物股份公司 2025 年 3 月 25 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等要求，公司董事会就在任独立董事 Yiu Leung Andy CHEUNG （张耀樑）、桂水发、刘建忠的独立性情况进行评估并出具如下专项意见： 经核查独立董事 Yiu Leung Andy CHEUNG（张耀樑）、桂水发、刘建忠的任 职经历以及签署的相关自查文件，上述人员未在公司担任除独立董事以外的任何 职务，也未在公司主要股东公司担任任何职务，与公司及其主要股东之间不存在 利害关系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立 性的情况，符合《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》中对独立董事独立性的相关要求。 董事会关于独立董事独立性自查情况的专项报告 ...

证券代码：688185 证券简称：康希诺 公告编号：2025-011 康希诺生物股份公司 2024 年度募集资金存放与实际使用情况专项报告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）董事会根据中国证券监督管理委 员会（以下简称"证监会"）《上市公司监管指引第 2 号—上市公司募集资金管 理和使用的监管要求》及《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》等有关规定，编制了截至 2024 年 12 月 31 日止公开发行 A 股股票 募集资金存放与实际使用情况的专项报告。现将截至 2024 年 12 月 31 日止募集 资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 经中国证监会《关于同意康希诺生物股份公司首次公开发行股票注册的批复》 （证监发行字[2020]1448 号文）核准，公司在上海证券交易所公开发行人民币普 通股（A 股）股票 24,800,000 股，每股发行价格为人民币 209.71 元，股票发行募 集资金总额为人民币 5,200,808 ...

Financial Performance - The company reported a net loss for the period, continuing its trend of not achieving profitability since its listing [3]. - The company reported a revenue of RMB 1.2 billion for the fiscal year 2024, representing a 15% increase compared to the previous year [14]. - The company achieved operating revenue of RMB 846,338,072.24 in 2024, a year-on-year increase of 137.01% [25]. - The net loss attributable to shareholders of the listed company was RMB 378,884,001.37, a decrease in loss of 74.45% compared to the previous year [25]. - The total assets at the end of 2024 were RMB 7,958,132,235.38, a decrease of 14.60% year-on-year [25]. - The basic earnings per share for 2024 was -RMB 1.53, compared to -RMB 6.01 in 2023 [24]. - The gross margin for the current fiscal year is reported at 60%, maintaining a stable level compared to last year [22]. - The total net profit from non-recurring items for 2024 was RMB 62,366,451.62, compared to RMB 128,356,172.58 in 2023 [31]. Research and Development - The company continues to focus on research and development of new products and technologies, although specific financial metrics are not provided in the current report [3]. - The R&D department is focusing on the development of a new mRNA vaccine, with an expected completion date for clinical trials in Q3 2024 [17]. - The company has allocated RMB 300 million for research and development in the upcoming year, a 30% increase from the previous budget [20]. - Research and development expenses accounted for 60.35% of operating revenue, a decrease of 124.95 percentage points from the previous year [24]. - The company has established five major technology platforms for vaccine research and development, enhancing its competitive product portfolio [72]. - The company has received 7 new patents during the reporting period, bringing the total number of granted patents to 57 [78]. - The company is focusing on the development of high-quality vaccine products to replace imports in developed markets, with specific products like MCV2 and MCV4 showing promising safety and immunogenicity [165]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by the end of 2025 [18]. - The company projects a revenue growth of 10% for the next fiscal year, driven by new product launches and market expansion strategies [16]. - The company is advancing its internationalization efforts, targeting Southeast Asia, the Middle East, North Africa, and South America for the commercialization of its quadrivalent meningococcal conjugate vaccine MCV4, which received registration in Indonesia in December 2024 [40]. - The company is exploring new strategies for market expansion and product development to enhance its competitive position in the vaccine industry [138]. - The company is actively expanding its product pipeline with various vaccines in different clinical stages, including those for meningitis and tuberculosis [45]. Corporate Governance - The board of directors confirmed the absence of any profit distribution plan or capital reserve transfer to increase share capital for the reporting period [5]. - The company has not disclosed any special arrangements regarding corporate governance [5]. - The company has established a governance structure that complies with regulatory requirements, ensuring effective operation and accountability [173]. - The company has proposed a profit distribution plan for the year 2023, which is currently under review [175]. - The company has not reported any changes in the governance structure of its red-chip architecture during the reporting period [176]. Risk Factors and Financial Management - The company has identified significant risk factors that may adversely affect its operations, as detailed in the management discussion section [3]. - The company is exposed to financial risks, including currency exchange risks related to overseas operations and potential asset impairment risks [96]. - The company has implemented strict risk control measures for derivative trading, ensuring that the scale and direction of trades match the hedged foreign exchange assets [157]. - The company is committed to improving operational efficiency through resource focus and cost control measures [170]. Product Development and Clinical Trials - The company is conducting Phase I clinical trials for a recombinant shingles vaccine in Canada, utilizing adenovirus vector technology to stimulate both cellular and humoral immunity, with production adhering to international quality standards [39]. - The company has completed Phase I clinical trials for PBPV (pneumococcal vaccine) with positive preliminary results [45]. - The company is advancing multiple vaccine projects, including a recombinant polio vaccine currently in clinical trials in Indonesia [84]. - The company has received acceptance for the drug registration application of PCV13, a 13-valent pneumococcal conjugate vaccine, indicating progress in its R&D pipeline [139]. Sales and Marketing - The company has established partnerships with three major healthcare organizations to enhance distribution channels and improve vaccine accessibility [23]. - The sales revenue from the two meningococcal conjugate vaccines reached approximately 793.79 million RMB, representing a year-on-year growth of 41.31% [35]. - The company is enhancing its corporate governance framework to align with best practices in the industry [181]. - The company is expanding its market presence in Asia, aiming to increase market share by 15% over the next two years [185]. Operational Efficiency - The company has optimized resource allocation, leading to a decrease in management and research expenses, and improved operational efficiency [26]. - The company reported a significant reduction in lease liabilities by 92.76% to ¥12,675,754.57 due to the exclusion of a subsidiary from consolidation [128]. - The company is committed to advancing the commercialization of existing products while maintaining significant investment in R&D for future pipeline products [93]. - The company has seen a trend of decreasing procurement amounts from the top five suppliers since 2023, indicating a diversification in supplier relationships [119]. Shareholder Engagement - The company held its first extraordinary shareholders' meeting of 2024 on February 21, where the third board of directors and the third supervisory board were elected [180]. - The company has proposed to revise its shareholder dividend return plan for the next three years (2023-2025) [1]. - The company has not reported any dissenting votes on the proposals presented at the shareholders' meeting, indicating strong shareholder support [175].

康希诺:2024年报净利润-3.79亿 同比增长74.44% 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -1.5300 | -6.0100 | 74.54 | -3.6800 | | 每股净资产（元） | 0 | 21.32 | -100 | 27.27 | | 每股公积金(元) | 26.58 | 26.57 | 0.04 | 26.7 | | 每股未分配利润(元) | -7.83 | -6.30 | -24.29 | -0.31 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 8.46 | 3.57 | 136.97 | 10.35 | | 净利润(亿元) | -3.79 | -14.83 | 74.44 | -9.09 | | 净资产收益率(%) | -7.44 | -24.67 | 69.84 | -12.36 | 数据四舍五入，查看更多财务数据>> | 持有数量(万股) 名称 ...

Financial Performance - Total revenue for 2024 reached ¥846,338,072.24, a year-on-year increase of 137.01%[4] - Net loss attributable to shareholders decreased to ¥378,884,001.37, a reduction of 74.45% compared to the previous year[6] - The company reported a significant reduction in operating losses by 80.62% and total losses by 80.74%[9] - The basic earnings per share improved to -¥1.53, compared to -¥6.01 in the previous year[4] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,958,132,235.38, a decrease of 14.60% year-on-year[4] Research and Development - Research and development expenses decreased significantly, contributing to improved operational efficiency[7] - The company focused on commercializing the ACYW135 meningococcal polysaccharide conjugate vaccine, which is the only four-valent meningococcal vaccine in the Chinese market[6] Operational Efficiency - The company optimized resource allocation and implemented cost-reduction measures, leading to a notable decrease in asset impairment losses[7] - The sales channel for the meningococcal vaccine was continuously developed, resulting in increased market penetration and sales volume[9] Risk Management - The company emphasizes the importance of monitoring investment risks as the financial data is preliminary and unaudited[10]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康希諾生物股份公司 呈交日期: 2025年2月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06185 | 說明 | H 股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 132,670,900 | RMB | | 1 RMB | | 132,670,900 | | 2. 股份分類 | 普通股 | 股份類別 | ...

Financial Projections - The company expects to achieve an operating revenue of between 825 million and 865 million CNY for the year 2024[4] - The projected net profit attributable to the parent company for 2024 is expected to be between -335 million and -385 million CNY[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -395 million and -450 million CNY for 2024[4] Historical Performance - In 2023, the company reported an operating revenue of 357.08 million CNY and a net loss attributable to the parent company of -1.48 billion CNY[6] Business Development - The company has focused on advancing the commercialization of the meningococcal conjugate vaccine and the development of non-COVID vaccine products[7] - The company has improved its sales channels and the market share of its exclusive product, the ACYW135 meningococcal polysaccharide conjugate vaccine, is continuously increasing[7] Operational Efficiency - Management expenses and research and development expenses have decreased year-on-year, contributing to improved operational efficiency[7] - The company has optimized resource allocation and implemented cost reduction measures, leading to a significant decrease in asset impairment losses compared to the previous year[7] Earnings Forecast Accuracy - There are no significant uncertainties affecting the accuracy of this earnings forecast[8] - The data provided is preliminary and the final audited financial data will be disclosed in the official annual report for 2024[9]

证券代码：688185 证券简称：康希诺 公告编号：2024-051 康希诺生物股份公司 自愿披露关于ACYW135群脑膜炎球菌多糖结合疫苗 （CRM197载体）药品补充申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 康希诺生物股份公司（以下简称"公司"）的 ACYW135 群脑膜炎球菌多糖 结合疫苗（CRM197 载体）（以下简称"MCV4"）药品补充申请（以下简称"补 充申请"）于近日获得国家药品监督管理局出具的《受理通知书》，受理号： CYSB2400306。现将相关情况公告如下： MCV4 的适用人群年龄范围扩大尚需获得药品补充申请批准通知书，本次补 充申请获受理不会对公司现阶段业绩产生重大影响。 公司将对该产品的后续进展情况及时履行信息披露义务，公司信息以公司指 定披露媒体以及上海证券交易所网站刊登的公告为准。敬请广大投资者谨慎决 策，注意投资风险。 特此公告。 康希诺生物股份公司董事会 一、产品及补充申请情况 公司的 MCV4 已获得国家药品监督管理局下发的《药品注册证书》，具体情 况详见公 ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 35.10, indicating a potential upside of 20.6% from the current price of HKD 29.15 [4][5]. Core Insights - The company achieved its first quarterly profit post-pandemic in Q3 2024, with revenue of HKD 264 million, representing a year-on-year increase of 76.1%. For the first three quarters, total revenue reached HKD 567 million, up 222.9% year-on-year, with a 36.9% growth after adjusting for expected returns of COVID-19 vaccines [2]. - The company's cost management has shown significant improvement, with a reduction in management and R&D expenses by 37.6% and 41.0% respectively, leading to a narrowed net loss of HKD 222 million for the first three quarters [2]. - The company's meningococcal vaccine, "曼海欣," has seen impressive growth, with revenue of HKD 516 million in the first three quarters, a 39.07% increase year-on-year. The product is expected to maintain its market position as the only MCV4 product in China [3]. Summary by Sections Financial Performance - In Q3 2024, the company reported a revenue of HKD 264 million, marking a 76.1% increase year-on-year. The total revenue for the first three quarters was HKD 567 million, reflecting a 222.9% increase year-on-year, with a 36.9% growth after accounting for expected returns of COVID-19 vaccines [2]. - The company managed to reduce its asset impairment losses by HKD 777 million year-on-year, resulting in a narrowed net loss of HKD 222 million for the first three quarters [2]. Product Pipeline and Growth Drivers - The company has multiple product pipelines progressing well, including the PCV13i vaccine, which has received acceptance for market application and is expected to be approved next year, providing a second growth point [4]. - The company is actively pursuing the expansion of its meningococcal vaccine for ages 4-6, with approval anticipated next year, which will enhance sales growth [3]. - The company has also received a USD 17 million grant from the Gates Foundation to advance the development of a restructured polio vaccine, indicating strong support for its R&D initiatives [4].

Revenue and Profitability - Total revenue for the nine months ended September 30, 2024, was RMB 263,646,520.16, representing a 76.09% increase compared to the same period last year[4] - Net profit attributable to shareholders for the reporting period was RMB 2,964,467.27, a significant recovery from a loss of RMB 222,409,418.57 in the previous year[4] - Basic earnings per share for the current period was RMB 0.01, compared to a loss of RMB 0.90 per share in the same period last year[5] - The company's operating revenue for the year-to-date period increased by 222.88%, reaching 238,757,612.38 CNY, with a year-on-year growth of 36.85% after excluding the impact of COVID-19 vaccine returns[9] - Sales revenue from the meningococcal vaccine product reached 516,153,650.93 CNY, representing a year-on-year increase of 39.07%[9] - The net loss attributable to shareholders of the listed company for the first three quarters was 222,409,418.57 CNY, significantly reduced by 762,620,235.90 CNY compared to the previous year[9] - The company achieved a single-quarter net profit attributable to shareholders of 2,964,467.27 CNY in the third quarter[9] - Total revenue for the first three quarters of 2024 was a loss of 227,196,536.24 RMB, compared to a loss of 1,454,919,925.84 RMB in the same period of 2023, indicating a significant improvement[23] - Operating profit for the first three quarters of 2024 was a loss of 222,830,476.31 RMB, compared to a loss of 1,415,383,868.45 RMB in the same period of 2023, reflecting a reduction in operational losses[23] - Total comprehensive income attributable to the parent company for the first three quarters of 2024 was a loss of (226,815,781.51) RMB, compared to a loss of (1,454,797,112.46) RMB in the same period of 2023[25] Assets and Liabilities - Total assets as of September 30, 2024, were RMB 7,989,566,970.77, a decrease of 14.26% from RMB 9,318,769,372.66 at the end of the previous year[5] - As of September 30, 2024, total current assets were RMB 4,369,254,431.78, down from RMB 5,180,827,776.61 at the end of 2023, reflecting a decline of about 16%[18] - Total non-current assets decreased to RMB 3,620,312,538.99 from RMB 4,137,941,596.05, representing a reduction of approximately 12.5%[19] - Total liabilities as of September 30, 2024, were RMB 2,926,151,613.50, down from RMB 4,031,354,058.75, indicating a decrease of about 27%[20] - The company's total assets decreased to RMB 7,989,566,970.77 from RMB 9,318,769,372.66, reflecting a decline of approximately 14.2%[21] - The company's retained earnings showed a negative balance of RMB (1,780,823,276.18) as of September 30, 2024, compared to RMB (1,558,413,857.61) at the end of 2023[21] - Cash and cash equivalents decreased to RMB 1,364,455,953.58 from RMB 2,821,595,241.10, a decline of approximately 52%[18] - Short-term borrowings were reduced to RMB 596,881,991.30 from RMB 854,082,887.35, indicating a decrease of about 30%[20] Research and Development - Research and development expenses totaled RMB 107,918,795.43, a decrease of 23.18% compared to the same period last year[5] - The ratio of R&D expenses to total revenue was 40.93%, down 52.89 percentage points from the previous year[5] - Research and development expenses as a percentage of operating revenue decreased by 210.45 percentage points compared to the previous year[12] - Research and development expenses for the first three quarters of 2024 amounted to RMB 272,272,224.71, a decrease of approximately 41% compared to RMB 461,673,523.32 in 2023[22] Cash Flow - The company reported a net cash flow from operating activities of RMB (287,414,483.35), indicating ongoing challenges in cash generation[4] - Cash flow from operating activities for the first three quarters of 2024 was a net outflow of 287,414,483.35 RMB, an improvement from a net outflow of 748,974,021.75 RMB in the same period of 2023[28] - The company’s cash outflow for operating activities totaled 897,365,298.94 RMB in the first three quarters of 2024, down from 1,364,783,068.46 RMB in the same period of 2023, indicating improved cash management[28] - Cash inflow from investment activities for the first three quarters of 2024 was 9,594,480,245.55 RMB, compared to 6,640,825,701.63 RMB in the same period of 2023, showing a substantial increase[28] - Cash inflow from financing activities for the first three quarters of 2024 was approximately $709.2 million, a decrease of 48.5% compared to $1.32 billion in the same period of 2023[29] - Cash outflow for debt repayment in the first three quarters of 2024 was approximately $884.9 million, down 37.1% from $1.41 billion in the first three quarters of 2023[29] - Net cash flow from financing activities for the first three quarters of 2024 was negative $232.9 million, compared to negative $131.3 million in the same period of 2023[29] - The ending cash and cash equivalents balance for the first three quarters of 2024 was approximately $868.9 million, a decrease of 63.0% from $2.35 billion at the end of the same period in 2023[29] - The impact of exchange rate changes on cash and cash equivalents was negative $882.2 thousand in the first three quarters of 2024, contrasting with a positive impact of $51.8 million in the same period of 2023[29] Government Subsidies and Non-Recurring Items - The company received government subsidies amounting to RMB 14,565,011.91, which are not included in non-recurring gains and losses[6] - The total non-recurring gains and losses for the current period amounted to RMB 9,686,646.95, compared to RMB 38,838,797.88 for the previous period[7] - Other comprehensive income after tax for the first three quarters of 2024 was 380,754.73 RMB, significantly higher than 122,813.38 RMB in the same period of 2023[24] - The company reported investment losses of (50,473,598.71) RMB in the first three quarters of 2024, a decline from investment income of 71,754,545.48 RMB in the same period of 2023[23] - The company incurred asset impairment losses of (10,101,389.63) RMB in the first three quarters of 2024, a significant decrease from (786,743,942.29) RMB in the same period of 2023[23] - The average return on equity increased by 2.52 percentage points for the reporting period[10] - The weighted average return on net assets was 0.06%, an increase of 2.52 percentage points from the previous year[5]